PREDIABET XAVF OMILLARI VA ULARNING SURUNKALI YURAK YETISHMOVCHILIGINING KLINIK NAMOYON BO‘LISHIGA TA'SIRI

Madina Soliyeva

Authors

Madina Soliyeva Gospital terapiya va endokrinologiya kafedrasi Endokrinologiya yo`nalishi magistranti Andijon Davlat Tibbiyot Instituti Author

Keywords:

surunkali yurak yetishmovchiligi, prediabet, insulin rezistentligi, xavf omillari, semizlik

Abstract

Mazkur tadqiqotning maqsadi surunkali yurak yetishmovchiligi (SYuY) bilan og‘rigan bemorlarda prediabet rivojlanishiga olib keluvchi asosiy xavf omillarini aniqlash hamda uglevod almashinuvi buzilishlarining kasallikning klinik kechishiga ta’sirini baholashdan iborat bo‘ldi. Tadqiqot Andijon Respublikasi ixtisoslashtirilgan ilmiy-amaliy tibbiyot markazi Kardiologiya filialida amalga oshirildi. Unda surunkali yurak yetishmovchiligi tashxisi qo‘yilgan 60 nafar bemor ishtirok etdi. Asosiy guruhni SYuY va prediabet aniqlangan 30 nafar bemor, nazorat guruhini esa uglevod almashinuvi buzilishlari kuzatilmagan 30 nafar SYuY bemori tashkil etdi. Barcha ishtirokchilarda klinik holat, antropometrik ko‘rsatkichlar, laborator tahlillar hamda surunkali yurak yetishmovchiligining funksional sinfi kompleks baholandi. Tadqiqot natijalariga ko‘ra, prediabet mavjud bemorlarda semizlik, abdominal semizlik va insulin rezistentligi sezilarli darajada ko‘proq uchrashi, shuningdek, surunkali yurak yetishmovchiligining klinik belgilari yanada yaqqol namoyon bo‘lishi aniqlandi. Olingan ma’lumotlar surunkali yurak yetishmovchiligi bo‘lgan bemorlarda prediabetni erta aniqlash va kardiometabolik asoratlarning oldini olish bo‘yicha profilaktik choralarni kuchaytirish zarurligini ko‘rsatadi.

Downloads

Download data is not yet available.

References

1. American Diabetes Association Professional Practice Committee. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2025 // Diabetes Care. – 2025. – Vol. 48, Suppl. 1. – P. S20–S39.

2. American Diabetes Association Professional Practice Committee. Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes—2025 // Diabetes Care. – 2025. – Vol. 48, Suppl. 1. – P. S40–S55.

3. Anker S. D., Butler J., Filippatos G., Ferreira J. P., Bocchi E., Böhm M., et al. Empagliflozin in patients with heart failure with preserved ejection fraction // The New England Journal of Medicine. – 2021. – Vol. 385, No. 16. – P. 1451–1461.

4. Bozkurt B., Coats A. J. S., Tsutsui H., Abdelhamid C. M., Adamopoulos S., Albert N., et al. Universal definition and classification of heart failure // Journal of Cardiac Failure. – 2021. – Vol. 27, No. 4. – P. 387–413.

5. Butler J., Khan M. S., Anker S. D., Verma S., Fitchett D., Ferreira J. P., et al. Effects of sodium-glucose cotransporter-2 inhibitors in heart failure regardless of diabetes status: A systematic review and meta-analysis // European Heart Journal. – 2022. – Vol. 43, No. 6. – P. 438–444.

6. International Diabetes Federation. IDF Diabetes Atlas. – 11th ed. – Brussels: International Diabetes Federation, 2025.

7. McDonagh T. A., Metra M., Adamo M., Gardner R. S., Baumbach A., Böhm M., et al. 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // European Heart Journal. – 2023. – Vol. 44, No. 37. – P. 3627–3639.

8. McMurray J. J. V., Solomon S. D., Inzucchi S. E., Køber L., Kosiborod M. N., Martinez F. A., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction // The New England Journal of Medicine. – 2019. – Vol. 381, No. 21. – P. 1995–2008.

9. Packer M., Anker S. D., Butler J., Filippatos G., Ferreira J. P., Pocock S. J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure // The New England Journal of Medicine. – 2020. – Vol. 383. – P. 1413–1424.

10. Solomon S. D., McMurray J. J. V., Claggett B., de Boer R. A., DeMets D., Hernandez A. F., et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction // The New England Journal of Medicine. – 2022. – Vol. 387. – P. 1089–1098.